The DZD has set up multicenter clinical studies to develop precision prevention and therapy measures, i.e. the right treatment for the right patient group at the right time (Precision Medicine). Topics include type 1 diabetes and type 2 diabetes, gestational diabetes, secondary diseases, treatment of fatty liver in diabetes and insulin resistance in the brain. The Germany-wide cooperation in the research network makes it possible to initiate such large-scale studies and recruit the necessary participants. In total, more than 5,000 test subjects have already participated in the studies, which are being conducted at up to ten study locations.
First results are already available. Studies have shown that there are different subtypes of prediabetes and diabetes. Not every subgroup has the same risk of developing diabetes or severe secondary diseases. In new studies, the DZD is now developing interventions and therapies tailored to the individual subgroups to prevent or at least delay the onset of the metabolic disease and its complications.
DZD Study Centers
Prof. Dr. Anette-Gabriele Ziegler
Helmholtz Zentrum München
Prof. Dr. Jochen Seißler, PD Dr. Andreas Lechner
Prof. Dr. Hans Hauner
Technische Universität München
Phone: 089–289 249 –16/ –25
Prof. Dr. Andreas Fritsche, Prof. Dr. Norbert Stefan,
Tübingen University Hospital
Prof. Dr. Michael Roden
German Diabetes Center
Prof. Dr. Andreas Pfeiffer
German Institute of Human Nutrition /
Phone: 033200–882778 oder 882774
Prof. Dr. Andreas Birkenfeld, Prof. Dr. Peter Schwarz, Prof. Dr. Stefan Bornstein
Dresden University Hospital
Prof. Dr. Julia Szendrödi
Heidelberg University Hospital
Phone: 06221 56-8606
Prof. Dr. Michael Stumvoll, Dr. Gesine Flehmig
Leipzig University Hospital
Prof. Dr. Sebastian Schmid
Schleswig-Holstein University Hospital
Phone: 0451 500 3878
Test Triangle Study
The "Test-Triangle" study examines whether the use of the "Triangle" smartphone app helps women after having had gestational diabetes to better integrate a healthy lifestyle into their daily lives.
The study is aimed at women who have been diagnosed with gestational diabetes during a recent pregnancy. This metabolic disorder is associated with an increased risk of developing type 2 diabetes later on. However, the right lifestyle can significantly reduce this risk. Unfortunately, young mothers have little time for their own health. For this reason, the "Triangle" smartphone app was specifically developed for this group. The app provides support to help lead a healthy lifestyle in the areas of exercise, nutrition and stress reduction. Users of the app are mentored by a qualified online coach who takes their individual needs into account and who adapts the content of the app accordingly. With the help of the app, more healthy habits can be incorporated into the everyday life of the participants step-by-step over a period of 6 months.
Recruitment for this study has been completed.
Prediabetes Lifestyle Intervention Study (PLIS, FollowUp)
Conventional lifestyle intervention is not sufficient to prevent type 2 diabetes in all people with prediabetes. Only individually tailored prevention can be effective here. In the completed multicenter Prediabetes Lifestyle Intervention Study (PLIS), the DZD set itself the goal of developing such personalized preventive measures. After extensive phenotyping, the PLIS study participants underwent different lifestyle programs with nutritional counseling and supervised physical activity. 1,145 patients were recruited for the PLIS study. To scientifically follow up this valuable cohort, the follow-up of the study participants was extended to a long-term observation over a period of 12 years after the intervention. Cluster analyses of the PLIS study identified first subtypes of prediabetes that have a particularly high risk of secondary diseases.
Recruitment for the study is now completed.
DZD Prediabetes Cohort
Prediabetes is the precursor stage of diabetes in which the blood glucose levels are already abnormal. In order to develop personalized prevention strategies for type 2 diabetes, the DZD, based on previous studies, formed a unique prediabetes cohort that is unique in Germany with 8,106 participants who are continuously being investigated. In these patients, the blood glucose concentrations of the oral glucose tolerance test were abnormal at the time of enrollment in the study, but no diabetes was present. The current data analysis showed that a family history of diabetes can already increase the risk of prediabetes by 40 percent. The participants will be monitored in follow-up studies.
The study has shown that the diabetes drug empagliflozin, an SGLT-2 inhibitor, can significantly reduce liver fat levels in patients. The study has been completed.
Prof. Dr. Andreas Birkenfeld
Contact Study Participation
Tel.: +49 (0)89-3187-2832